{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:00:51Z","timestamp":1791986451072,"version":"4.4.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/nrurol.2017.16","type":"journal-article","created":{"date-parts":[[2017,3,4]],"date-time":"2017-03-04T03:05:48Z","timestamp":1488596748000},"page":"244-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":160,"title":["BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG"],"prefix":"10.1038","volume":"14","author":[{"given":"Ashish M.","family":"Kamat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Sundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Lamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Boehle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Brausi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Persad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Soloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,21]]},"reference":[{"key":"BFnrurol201716_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2016","unstructured":"Babjuk, M.  et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 71, 447\u2013461 (2016).","journal-title":"Eur Urol."},{"key":"BFnrurol201716_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","volume":"192","author":"AM Kamat","year":"2014","unstructured":"Kamat, A. M.  et al. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J. Urol. 192, 305\u2013315 (2014).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR3","first-page":"CD001986","volume":"4","author":"M Shelley","year":"2000","unstructured":"Shelley, M.  et al. Intravesical bacillus Calmette\u2013Gu\u00e9rin in Ta and T1 bladder cancer (review). Cochrane Database Syst. Rev. 4, CD001986 (2000).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrurol201716_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.juro.2013.08.022","volume":"191","author":"JP Sfakianos","year":"2014","unstructured":"Sfakianos, J. P., Kim, P. H., Hakimi, A. A. & Herr, H. W. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette\u2013Guerin. J. Urol. 191, 341\u2013345 (2014).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.juro.2013.07.102","volume":"191","author":"D Lamm","year":"2014","unstructured":"Lamm, D.  et al. Review article defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. J. Urol. 191, 20\u201327 (2014).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier, S.  et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta\u2013T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Guerin. Eur. Urol. 69, 60\u201369 (2016).","journal-title":"Eur. Urol."},{"key":"BFnrurol201716_CR7","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S0022-5347(17)40002-4","volume":"143","author":"JA Mart\u00ednez-Pi\u00f1eiro","year":"1990","unstructured":"Mart\u00ednez-Pi\u00f1eiro, J. A.  et al. Bacillus Calmette\u2013Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J. Urol. 143, 502\u2013506 (1990).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR8","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat, A. M.  et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J. Clin. Oncol. 34, 1935\u20131944 (2016).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201716_CR9","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.eururo.2016.02.031","volume":"70","author":"CO Mmeje","year":"2016","unstructured":"Mmeje, C. O.  et al. Papillary recurrence of bladder cancer at first evaluation after induction bacillus Calmette\u2013Guerin therapy: implication for clinical trial design. Eur Urol. 70, 778\u2013785 (2016).","journal-title":"Eur Urol."},{"key":"BFnrurol201716_CR10","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm, D. L.  et al. Maintenance bacillus Calmette\u2013Guerin immunotherapy for recurrent Ta, T1, and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163, 1124\u20131129 (2000).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A Bohle","year":"2003","unstructured":"Bohle, A., Jocham, D. & Bock, P. Intravesical bacillus Calmette\u2013Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies of recurrence and toxicity. J. Urol. 169, 90\u201395 (2003).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"P-U Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m, P.-U.  et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette\u2013Guerin for non-muscle-invasive bladder cancer. Eur. Urol. 56, 247\u2013256 (2009).","journal-title":"Eur. Urol."},{"key":"BFnrurol201716_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1464-410X.2010.09891.x","volume":"108","author":"S Hinotsu","year":"2010","unstructured":"Hinotsu, S.  et al. Maintenance therapy with bacillus Calmette\u2013Gu\u00e9rin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int. 108, 187\u2013195 (2010).","journal-title":"BJU Int."},{"key":"BFnrurol201716_CR14","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/1471-2407-13-332","volume":"13","author":"S Zhu","year":"2013","unstructured":"Zhu, S.  et al. Optimal schedule of bacillus Calmette\u2013Guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies. BMC Cancer 13, 332 (2013).","journal-title":"BMC Cancer"},{"key":"BFnrurol201716_CR15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens, J.  et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette\u2013Guerin rin in intermediate- and high- risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur. Urol. 63, 462\u2013472 (2013).","journal-title":"Eur. Urol."},{"key":"BFnrurol201716_CR16","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"Sylvester, R. J.  et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette\u2013Guerin, and bacillus Calmette\u2013Guerin plus isoniazid in patients with intermediate- and high-risk. Eur. Urol. 57, 766\u2013773 (2010).","journal-title":"Eur. Urol."},{"key":"BFnrurol201716_CR17","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/S0022-5347(05)66333-1","volume":"165","author":"J Palou","year":"2001","unstructured":"Palou, J.  et al. Control group and maintenance treatment with bacillus Calmette\u2013Guerin for carcinoma in siute and\/or high grade bladder tumors. J. Urol. 165, 1488\u20131491 (2001).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.eururo.2013.10.016","volume":"65","author":"AM Kamat","year":"2014","unstructured":"Kamat, A. M. & Porten, S. Myths and mysteries surrounding bacillus Calmette\u2013Guerin therapy for bladder cancer. Eur. Urol. 65, 267\u2013269 (2014).","journal-title":"Eur. Urol."},{"key":"BFnrurol201716_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrurol.2015.58","volume":"12","author":"AM Kamat","year":"2015","unstructured":"Kamat, A. M.  et al. Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat. Rev. Urol. 12, 225\u2013235 (2015).","journal-title":"Nat. Rev. Urol."},{"key":"BFnrurol201716_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eururo.2012.08.009","volume":"63","author":"G Gakis","year":"2013","unstructured":"Gakis, G.  et al. ICUD-EAU international consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 63, 45\u201357 (2013).","journal-title":"Eur. Urol."},{"key":"BFnrurol201716_CR21","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","volume":"64","author":"M Babjuk","year":"2013","unstructured":"Babjuk, M.  et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur. Urol. 64, 639\u2013653 (2013).","journal-title":"Eur. Urol."},{"key":"BFnrurol201716_CR22","volume-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","author":"SS Chang","year":"2016","unstructured":"Chang, S. S.  et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline [online] \n                    https:\/\/www.auanet.org\/common\/pdf\/education\/clinical-guidance\/Non-Muscle-Invasive-Bladder-Cancer.pdf\n                    \n                   (2016)."},{"key":"BFnrurol201716_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/BLC-159002","volume":"1","author":"S Lerner","year":"2015","unstructured":"Lerner, S.  et al. Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. Bl Cancer 1, 29\u201330 (2015).","journal-title":"Bl Cancer"},{"key":"BFnrurol201716_CR24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","volume":"83","author":"JP Jarow","year":"2013","unstructured":"Jarow, J. P.  et al. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. Urology 83, 262\u2013265 (2013).","journal-title":"Urology"},{"key":"BFnrurol201716_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ucl.2013.01.012","volume":"40","author":"JB Shah","year":"2013","unstructured":"Shah, J. B. & Kamat, A. M. Strategies for optimizing bacillus Calmette\u2013Guerin. Urol. Clin. North Am. 40, 211\u2013218 (2013).","journal-title":"Urol. Clin. North Am."},{"key":"BFnrurol201716_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3233\/BLC-160048","volume":"2","author":"AM Kamat","year":"2016","unstructured":"Kamat, A. M., Cookson, M., Witjes, J. A., Stenzl, A. & Grossman, H. B. The impact of blue light cystoscopy with hexaminolevulinate (HAL) on progression of bladder cancer \u2014 a new analysis. Bl Cancer 2, 273\u2013278 (2016).","journal-title":"Bl Cancer"},{"key":"BFnrurol201716_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2012.08.061","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger, M.  et al. ICUD-EAU international consultation on bladder cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 63, 36\u201344 (2013).","journal-title":"Eur. Urol."},{"key":"BFnrurol201716_CR28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2013.09.049","volume":"65","author":"D Birkha","year":"2014","unstructured":"Birkha, D., Recker, F., Thalmann, G. N. & Giannarini, G. Bacillus Calmette\u2013Guerin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra. Eur. Urol. 65, 825\u2013831 (2014).","journal-title":"Eur. Urol."},{"key":"BFnrurol201716_CR29","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","volume":"166","author":"HW Herr","year":"2001","unstructured":"Herr, H. W. & Sogani, P. C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J. Urol. 166, 1296\u20131299 (2001).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR30","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.juro.2016.01.087","volume":"195","author":"CR Haas","year":"2016","unstructured":"Haas, C. R.  et al. The timing of radical cystectomy for bacillus Calmette\u2013Guerin failure: comparison of outcomes and risk factors for prognosis. J. Urol. 195, 1704\u20131709 (2016).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR31","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.juro.2010.01.025","volume":"183","author":"D Tilki","year":"2010","unstructured":"Tilki, D.  et al. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J. Urol. 183, 1757\u20131763 (2010).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.eururo.2014.01.029","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow, J. J.  et al. Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. Eur. Urol. 66, 569\u2013576 (2014).","journal-title":"Eur. Urol."},{"key":"BFnrurol201716_CR33","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.juro.2010.06.007","volume":"184","author":"CJ Stimson","year":"2010","unstructured":"Stimson, C. J.  et al. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J. Urol. 184, 1296\u20131300 (2010).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR34","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.eururo.2014.12.002","volume":"67","author":"LS Hounsome","year":"2015","unstructured":"Hounsome, L. S., Verne, J., Mcgrath, J. S. & Gillatt, D. A. Trends in operative caseload and mortality rates after radical cystectomy for bladder cancer in England for 1998\u20132010. Eur. Urol. 67, 1056\u20131062 (2015).","journal-title":"Eur. Urol."},{"key":"BFnrurol201716_CR35","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.urology.2010.07.537","volume":"77","author":"D Liberman","year":"2011","unstructured":"Liberman, D.  et al. Septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology 77, 660\u2013666 (2011).","journal-title":"Urology"},{"key":"BFnrurol201716_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0936-6555(05)80838-6","volume":"3","author":"MK Gospodarowicz","year":"1991","unstructured":"Gospodarowicz, M. K.  et al. Bladder cancer: long-term follow-up results of patients treated with radical radiation. Clin. Oncol. (R. Coll. Radiol.) 3, 155\u2013161 (1991).","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"BFnrurol201716_CR37","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.juro.2007.05.024","volume":"178","author":"SJ Harland","year":"2007","unstructured":"Harland, S. J.  et al. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J. Urol. 178, 807\u2013813 (2007).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR38","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1200\/JCO.2006.05.8149","volume":"24","author":"C Weiss","year":"2016","unstructured":"Weiss, C., Wolze, C., Engehausen, D. G., Ott, O. J. & Krause, F. S. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J. Clin. Oncol. 24, 2318\u20132324 (2016).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201716_CR39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1464-410X.2008.08299.x","volume":"104","author":"JY Wo","year":"2008","unstructured":"Wo, J. Y.  et al. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette\u2013Gu\u00e9rin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary? BJU Int. 104, 179\u2013183 (2008).","journal-title":"BJU Int."},{"key":"BFnrurol201716_CR40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0022-5347(17)47381-2","volume":"134","author":"W Shipley","year":"2007","unstructured":"Shipley, W.  et al. Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. J. Urol. 134, 679\u2013683 (2007).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR41","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00981656?term=00981656&rank=1\n                    \n                   (2015)."},{"key":"BFnrurol201716_CR42","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","volume":"163","author":"G Steinberg","year":"2000","unstructured":"Steinberg, G.  et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette\u2013Guerin refractory carcinoma in situ of the bladder. J. Urol. 163, 761\u2013767 (2000).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR43","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","volume":"31","author":"CPN Dinney","year":"2013","unstructured":"Dinney, C. P. N.  et al. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Gu\u00e9rin. Urol. Oncol. 31, 1635\u20131642 (2013).","journal-title":"Urol. Oncol."},{"key":"BFnrurol201716_CR44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/1756287214541798","volume":"6","author":"MS Cookson","year":"2014","unstructured":"Cookson, M. S.  et al. Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder. Ther. Adv. Urol. 6, 181\u2013191 (2014).","journal-title":"Ther. Adv. Urol."},{"key":"BFnrurol201716_CR45","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","volume":"20","author":"BG Dalbagni","year":"2002","unstructured":"Dalbagni, B. G.  et al. Phase I trial of intravesical gemcitabine Calmette\u2013Guerin-refractory transitional-cell carcinoma of the bladder. J. Clin. Oncol. 20, 3193\u20133198 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201716_CR46","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","volume":"24","author":"G Dalbagni","year":"2006","unstructured":"Dalbagni, G.  et al. Phase II trial of intravesical gemcitabine in bacille Calmette\u2013Gu\u00e9rin-refractory transitional cell carcinoma of the bladder. J. Clin. Oncol. 24, 2729\u20132734 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201716_CR47","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","volume":"190","author":"EC Skinner","year":"2013","unstructured":"Skinner, E. C.  et al. SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence rin after 2 prior courses of intravesical bacillus Calmette\u2013Guerin. J. Urol. 190, 1200\u20131204 (2013).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR48","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/cncr.24914","volume":"116","author":"GDi Lorenzo","year":"2010","unstructured":"Lorenzo, G. Di, Perdona, S.  et al. Gemcitabine versus bacille Calmette\u2013Guerin after initial bacille Calmette\u2013Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 116, 1893\u20131900 (2010).","journal-title":"Cancer"},{"key":"BFnrurol201716_CR49","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","volume":"28","author":"R Addeo","year":"2010","unstructured":"Addeo, R.  et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J. Clin. Oncol. 28, 543\u2013548 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201716_CR50","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.urology.2009.06.112","volume":"75","author":"MA Laudano","year":"2010","unstructured":"Laudano, M. A.  et al. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer. Urology 75, 134\u2013137 (2010).","journal-title":"Urology"},{"key":"BFnrurol201716_CR51","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","volume":"189","author":"LJ Barlow","year":"2013","unstructured":"Barlow, L. J., Mckiernan, J. M. & Benson, M. C. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette\u2013Gu\u00e9rin therapy. J. Urol. 189, 834\u2013839 (2013).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR52","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.juro.2014.06.084","volume":"192","author":"JM Mckiernan","year":"2014","unstructured":"Mckiernan, J. M.  et al. Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette\u2013Guerin treatment failure. J. Urol. 192, 1633\u20131638 (2014).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11934-016-0594-2","volume":"17","author":"KN Velaer","year":"2016","unstructured":"Velaer, K. N., Steinberg, R. L., Thomas, L. J., O'Donnell, M. A. & Nepple, K. G. Experience with sequential intravesical gemcitabine and docetaxel as salvage therapy for non-muscle invasive bladder cancer. Curr. Urol. Rep. 17, 1\u20135 (2016).","journal-title":"Curr. Urol. Rep."},{"key":"BFnrurol201716_CR54","doi-asserted-by":"publisher","first-page":"35.e15","DOI":"10.1016\/j.urolonc.2013.01.009","volume":"32","author":"AJ Lightfoot","year":"2014","unstructured":"Lightfoot, A. J.  et al. Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. Urol. Oncol. 32, 35.e15\u201335.e19 (2014).","journal-title":"Urol. Oncol."},{"key":"BFnrurol201716_CR55","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/S0090-4295(97)00625-0","volume":"51","author":"M Brausi","year":"1998","unstructured":"Brausi, M.  et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study. Urology 51, 506\u2013509 (1998).","journal-title":"Urology"},{"key":"BFnrurol201716_CR56","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/jps.2600780502","volume":"78","author":"Y Chien","year":"1989","unstructured":"Chien, Y. & Banga, A. Iontophoretic (transdermal) delivery of drugs: overview of historical development. J. Pharm. Sci. 78, 353\u2013354 (1989).","journal-title":"J. Pharm. Sci."},{"key":"BFnrurol201716_CR57","first-page":"4912","volume":"59","author":"SM Di Stasi","year":"1999","unstructured":"Di Stasi, S. M.  et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration\u2013depth profiles studies. Cancer Res. 59, 4912\u20134918 (1999).","journal-title":"Cancer Res."},{"key":"BFnrurol201716_CR58","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S1470-2045(11)70190-5","volume":"12","author":"SM Di Stasi","year":"2011","unstructured":"Di Stasi, S. M.  et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 12, 871\u2013879 (2011).","journal-title":"Lancet Oncol."},{"key":"BFnrurol201716_CR59","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","volume":"7","author":"SM Di Stasi","year":"2006","unstructured":"Di Stasi, S. M.  et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 7, 43\u201351 (2006).","journal-title":"Lancet Oncol."},{"key":"BFnrurol201716_CR60","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.juro.2016.01.103","volume":"195","author":"C Gan","year":"2016","unstructured":"Gan, C.  et al. Sequential bacillus Calmette\u2013Guerin\/electromotive drug administration of mitomycin C as the standard intravesical regimen in high risk nonmuscle invasive bladder cancer: 2-year outcomes. J. Urol. 195, 1697\u20131703 (2016).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR61","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","volume":"170","author":"SM Di Stasi","year":"2003","unstructured":"Di Stasi, S. M.  et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superfical bladder cancer: a prospective randomized study. J. Urol. 170, 777\u2013782 (2003).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR62","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.juro.2014.03.101","volume":"192","author":"TJ Arends","year":"2014","unstructured":"Arends, T. J., van der Heijden, A. G. & Witjes, J. A. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J. Urol. 192, 708\u2013713 (2014).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR63","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/02656736.2016.1140232","volume":"32","author":"H van Valenberga","year":"2016","unstructured":"van Valenberga, H., Colombo, R. & Witjes, F. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. Int. J. Hyperthermia 32, 351\u2013362 (2016).","journal-title":"Int. J. Hyperthermia"},{"key":"BFnrurol201716_CR64","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","volume":"182","author":"O Nativ","year":"2009","unstructured":"Nativ, O.  et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette\u2013Guerin. J. Urol. 182, 1313\u20131317 (2009).","journal-title":"J. Urol."},{"issue":"Suppl. 1","key":"BFnrurol201716_CR65","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1464-410X.2009.09151.x","volume":"106","author":"B Ayres","year":"2010","unstructured":"Ayres, B., Connor, A., Corbishley, C. & Bailey, M. Radiofrequency hyperthermia and mitomycin C for the management of frail patients with high-risk non-muscle invasive bladder cancer who fail intravesical BCG treatment. BJU Int. 106 (Suppl. 1), 8, abstr.132 (2010).","journal-title":"BJU Int."},{"key":"BFnrurol201716_CR66","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2217\/fon.12.90","volume":"8","author":"B Moskovitz","year":"2012","unstructured":"Moskovitz, B., Halachmi, S., Moskovitz, M. & Nativ, O. 10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer. Future Oncol. 8, 1041\u20131049 (2012).","journal-title":"Future Oncol."},{"key":"BFnrurol201716_CR67","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000435788","volume":"96","author":"P Sooriakumaran","year":"2016","unstructured":"Sooriakumaran, P.  et al. Predictive factors for time to progression after hyperthermic mitomycin C treatment for high-risk non-muscle invasive urothelial carcinoma of the bladder: an observational cohort study of 97 patients. Urol. Int. 96, 83\u201390 (2016).","journal-title":"Urol. Int."},{"key":"BFnrurol201716_CR68","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","volume":"27","author":"JA Witjes","year":"2009","unstructured":"Witjes, J. A., Hendricksen, K. & Nativ, O. R. O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo\u00ae working party. World J. Urol. 27, 319\u2013324 (2009).","journal-title":"World J. Urol."},{"key":"BFnrurol201716_CR69","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.urolonc.2009.02.012","volume":"29","author":"S Halachmi","year":"2011","unstructured":"Halachmi, S.  et al. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol. Oncol. 29, 259\u2013264 (2011).","journal-title":"Urol. Oncol."},{"key":"BFnrurol201716_CR70","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","volume":"60","author":"RJM Lammers","year":"2011","unstructured":"Lammers, R. J. M., Witjes, J. A., Inman, B. A. & Leibovitch, I. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur. Urol. 60, 81\u201393 (2011).","journal-title":"Eur. Urol."},{"key":"BFnrurol201716_CR71","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"TJH Arends","year":"2016","unstructured":"Arends, T. J. H.  et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette\u2013Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur. Urol. 69, 1046\u20131052 (2016).","journal-title":"Eur. Urol."},{"key":"BFnrurol201716_CR72","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0090-4295(97)00067-8","volume":"49","author":"T Bui","year":"1997","unstructured":"Bui, T. & Schellhammer, F. Additional bacillus Calmette\u2013Guerin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 49, 687\u2013691 (1997).","journal-title":"Urology"},{"key":"BFnrurol201716_CR73","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0094-0143(05)70241-X","volume":"27","author":"G Dalbagni","year":"2000","unstructured":"Dalbagni, G. & Herr, H. W. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol. Clin. North Am. 27, 137\u2013146 (2000).","journal-title":"Urol. Clin. North Am."},{"key":"BFnrurol201716_CR74","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","volume":"173","author":"TMDE Reijke","year":"2005","unstructured":"Reijke, T. M.D. E.  et al. Bacillus Calmette\u2013Guerin versus epirubicin for primary, secondary, or concurrent carcinoma in situ of the bladder: results of a European organization for the research and treatment of cancer \u2014 Genitourinary Group phase III trial (30906). J. Urol. 173, 405\u2013409 (2005).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR75","unstructured":"NCCN clinical practice guidelines in oncology: bladder cancer. NCCN [online] \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asporg\n                    \n                   (2016)."},{"key":"BFnrurol201716_CR76","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","volume":"137","author":"W Catalona","year":"1987","unstructured":"Catalona, W., Hudson, M., Gillen, D., Andriole, G. & Ratliff, T. Risks and benefits of repeated courses of intravesical bacillus Calmette\u2013Guerin therapy for superficial bladder cancer. J. Urol. 137, 220\u2013224 (1987).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR77","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3233\/BLC-150039","volume":"2","author":"RL Steinberg","year":"2016","unstructured":"Steinberg, R. L., Thomas, L. J., Mott, S. L. & O'Donnell, M. A. Bacillus Calmette\u2013Guerin (BCG) treatment failures with non-muscle invasive bladder cancer: a data-driven definition for BCG unresponsive disease. Bl Cancer 2, 215\u2013224 (2016).","journal-title":"Bl Cancer"},{"key":"BFnrurol201716_CR78","doi-asserted-by":"publisher","first-page":"8973","DOI":"10.1158\/0008-5472.CAN-04-1909","volume":"2004","author":"A Papageorgiou","year":"2004","unstructured":"Papageorgiou, A.  et al. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res. 2004, 8973\u20138979 (2004).","journal-title":"Cancer Res."},{"key":"BFnrurol201716_CR79","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","volume":"24","author":"FN Joudi","year":"2006","unstructured":"Joudi, F. N., Smith, B. J., & O'Donnell, M. A. Final results from a national multicenter phase II trial of combination bacillus Calmette\u2013Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol. Oncol. 24, 344\u2013348 (2006).","journal-title":"Urol. Oncol."},{"key":"BFnrurol201716_CR80","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","volume":"71","author":"BL Gallagher","year":"2008","unstructured":"Gallagher, B. L., Joudi, F. N., Maym\u00ed, J. L. & O'Donnell, M. A. Impact of previous bacille Calmette\u2013Gu\u00e9rin failure pattern on subsequent response to bacille Calmette\u2013Guerin plus interferon intravesical therapy. Urology 71, 297\u2013301 (2008).","journal-title":"Urology"},{"key":"BFnrurol201716_CR81","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","volume":"184","author":"KG Nepple","year":"2010","unstructured":"Nepple, K. G.  et al. Bacillus Calmette\u2013Gu\u00e9rin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J. Urol. 184, 1915\u20131919 (2010).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR82","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.juro.2011.04.073","volume":"186","author":"HM Rosevear","year":"2011","unstructured":"Rosevear, H. M.  et al. Factors affecting response to bacillus Calmette\u2013Gu\u00e9rin plus interferon for urothelial carcinoma in situ. J. Urol. 186, 817\u2013823 (2011).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR83","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000281474","volume":"44","author":"F Rucker","year":"1989","unstructured":"Rucker, F. & Rubin, H. Variation of the immunosystem by ciclosporin and keyhole-limpet hemocyanin \u2014 are there effects on chemically induced bladder carcinoma? Urol. Int. 44, 77\u201380 (1989).","journal-title":"Urol. Int."},{"key":"BFnrurol201716_CR84","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1200\/JCO.2011.39.2936","volume":"30","author":"RJM Lammers","year":"2012","unstructured":"Lammers, R. J. M., Witjes, W. P. J., Janzing-Pastors, M. H., Caris, C. T. & Witjes, J. A. Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. J. Clin. Oncol. 30, 2273\u20132279 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201716_CR85","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1159\/000020051","volume":"36","author":"WP Witjes","year":"1999","unstructured":"Witjes, W. P.  et al. Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. Eur. Urol. 36, 576\u2013581 (1999).","journal-title":"Eur. Urol."},{"key":"BFnrurol201716_CR86","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.urolonc.2005.05.028","volume":"23","author":"MF Sarosdy","year":"2005","unstructured":"Sarosdy, M. F.  et al. A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette\u2013Gu\u00e9rin for carcinoma in situ of the bladder: a Southwest Oncology Group study. Urol. Oncol. 23, 386\u2013389 (2005).","journal-title":"Urol. Oncol."},{"key":"BFnrurol201716_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.3003586","volume":"4","author":"C Biot","year":"2012","unstructured":"Biot, C.  et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci. Transl Med. 4, 1\u201310 (2012).","journal-title":"Sci. Transl Med."},{"key":"BFnrurol201716_CR88","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","volume":"5","author":"BRA Badalament","year":"1987","unstructured":"Badalament, B. R. A.  et al. A Prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette\u2013Guerin therapy of superficial bladder cancer. J. Clin. Oncol. 5, 441\u2013449 (1987).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201716_CR89","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000282516","volume":"51","author":"JA Witjes","year":"1993","unstructured":"Witjes, J. A., Fransen, M. P. H., van der Meijden, A. P. M., Doesburg, W. H. & Debruyne, F. M. J. Use of maintenance intravesical bacillus Calmette\u2013Gu\u00e9rin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study. Urol. Int. 51, 67\u201372 (1993).","journal-title":"Urol. Int."},{"key":"BFnrurol201716_CR90","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02326168?term=02326168&rank=1\n                    \n                   (2015)."},{"key":"BFnrurol201716_CR91","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/sj.bjc.6690038","volume":"79","author":"MC Filion","year":"1999","unstructured":"Filion, M. C., L\u00e9picier, P., Morales, A. & Phillips, N. C. Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells. Br. J. Cancer 79, 229\u2013235 (1999).","journal-title":"Br. J. Cancer"},{"key":"BFnrurol201716_CR92","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","volume":"193","author":"A Morales","year":"2015","unstructured":"Morales, A.  et al. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression rin after failed treatment with bacillus Calmette\u2013Guerin. J. Urol. 193, 1135\u20131143 (2015).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR93","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles, T.  et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558\u2013562 (2014).","journal-title":"Nature"},{"key":"BFnrurol201716_CR94","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E.  et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"BFnrurol201716_CR95","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02625961?term=02625961&rank=1\n                    \n                   (2017)."},{"issue":"Suppl.","key":"BFnrurol201716_CR96","doi-asserted-by":"publisher","first-page":"TPS4576","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS4576","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat, A. M. KEYNOTE-057: phase 2 study of pembrolizumab for patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC) [abstract]. J. Clin. Oncol. 34 (Suppl.), TPS4576 (2016).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201716_CR97","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","volume":"188","author":"JM Burke","year":"2012","unstructured":"Burke, J. M.  et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J. Urol. 188, 2391\u20132397 (2012).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR98","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02365818?term=02365818&rank=1\n                    \n                   (2016)."},{"key":"BFnrurol201716_CR99","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/sj.cgt.7700488","volume":"9","author":"M Yamashita","year":"2002","unstructured":"Yamashita, M.  et al. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther. 9, 687\u2013691 (2002).","journal-title":"Cancer Gene Ther."},{"key":"BFnrurol201716_CR100","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","volume":"190","author":"CPN Dinney","year":"2013","unstructured":"Dinney, C. P. N.  et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for bacillus Calmette\u2013Gu\u00e9rin failures in nonmuscle invasive bladder cancer. J. Urol. 190, 850\u2013856 (2013).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR101","unstructured":"Dinney, C. P. Emerging therapy for BCG unresponsive NMIBC. Presented at the Society of Urologic Oncology Winter Meeting (Washington, D.C.), SUO-CTC Scientific Session (2015)."},{"issue":"Suppl.","key":"BFnrurol201716_CR102","first-page":"e1085","volume":"195","author":"D Sundi","year":"2016","unstructured":"Sundi, D.  et al. In vitro effects of interferon alpha in bladder cancer: immune checkpoint expression and microRNA and mRNA genomic profiling [abstract MP83-12]. J. Urol. 195 (Suppl.), e1085 (2016).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR103","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02773849?term=02773849&rank=1\n                    \n                   (2017)."},{"key":"BFnrurol201716_CR104","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/S0022-5347(05)66239-8","volume":"165","author":"R Waidelich","year":"2001","unstructured":"Waidelich, R., Stepp, H., Baumgartner, R. & Weninger, E. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J. Urol. 165, 1904\u20131907 (2001).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR105","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.urolonc.2012.02.007","volume":"31","author":"MJ Bader","year":"2013","unstructured":"Bader, M. J.  et al. Photodynamic therapy of bladder cancer \u2014 a phase I study using hexaminolevulinate (HAL). Urol. Oncol. 31, 1178\u20131183 (2013).","journal-title":"Urol. Oncol."},{"key":"BFnrurol201716_CR106","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat, A. M.  et al. Bladder cancer. Lancet 388, 2796\u20132810 (2016).","journal-title":"Lancet"},{"key":"BFnrurol201716_CR107","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrurol.2015.231","volume":"12","author":"K van Kessel","year":"2015","unstructured":"van Kessel, K., Zuiverloon, T., Alberts, A., Boormans, J. & Zwarthoff, E. Targeted therapies in bladder cancer: an overview of in vivo research. Nat. Rev. Urol. 12, 681\u2013694 (2015).","journal-title":"Nat. Rev. Urol."},{"key":"BFnrurol201716_CR108","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1200\/JCO.2011.37.7002","volume":"30","author":"TK Choueiri","year":"2012","unstructured":"Choueiri, T. K.  et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J. Clin. Oncol. 30, 507\u2013512 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 6","key":"BFnrurol201716_CR109","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/jco.2013.31.6_suppl.255","volume":"31","author":"MI Milowsky","year":"2013","unstructured":"Milowsky, M. I.  et al. Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3 [abstract]. J. Clin. Oncol. 31 (Suppl. 6), 255 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201716_CR110","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","volume":"25","author":"MHA Hussain","year":"2016","unstructured":"Hussain, M. H. A.  et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu\u2013positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute Trial. J. Clin. Oncol. 25, 2218\u20132224 (2016).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol201716_CR111","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01732107?term=01732107&rank=1\n                    \n                   (2016)."},{"key":"BFnrurol201716_CR112","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01259063?term=01259063&rank=1\n                    \n                   (2016)."},{"key":"BFnrurol201716_CR113","first-page":"313","volume":"4","author":"M Kowalski","year":"2010","unstructured":"Kowalski, M.  et al. A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients. Drug Des. Devel. Ther. 4, 313\u2013230 (2010).","journal-title":"Drug Des. Devel. Ther."},{"key":"BFnrurol201716_CR114","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02449239?term=02449239&rank=1\n                    \n                   (2016)."},{"key":"BFnrurol201716_CR115","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01118351?term=01118351&rank=1\n                    \n                   (2015)."},{"key":"BFnrurol201716_CR116","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ucl.2013.01.008","volume":"40","author":"JJ Ahn","year":"2013","unstructured":"Ahn, J. J. & Mckiernan, J. M. New agents for bacillus Calmette\u2013Guerin-refractory bladder cancer. Urol. Clin. North Am. 40, 219\u2013232 (2013).","journal-title":"Urol. Clin. North Am."},{"key":"BFnrurol201716_CR117","doi-asserted-by":"publisher","first-page":"7765","DOI":"10.1158\/1078-0432.CCR-11-1817","volume":"17","author":"MN Fishman","year":"2011","unstructured":"Fishman, M. N.  et al. Phase I trial of ALT-801, an interleukin-2\/T-cell receptor fusion protein targeting p53 (aa264-272)\/HLA-A*0201 complex, in patients with advanced malignancies. Clin. Cancer Res. 17, 7765\u20137776 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol201716_CR118","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01625260?term=01625260&rank=1\n                    \n                   (2017)."},{"key":"BFnrurol201716_CR119","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/jps.22309","volume":"100","author":"J Chen","year":"2011","unstructured":"Chen, J., Leu, Y., Fang, C., Chen, C. & Fang, J. Thermosensitive hydrogels composed of hyaluronic acid and gelatin as carriers for the intravesical administration of cisplatin. J. Pharm. Sci. 100, 655\u2013666 (2011).","journal-title":"J. Pharm. Sci."},{"key":"BFnrurol201716_CR120","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02701023?term=02701023&rank=1\n                    \n                   (2016)."},{"key":"BFnrurol201716_CR121","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02720367?term=02720367&rank=1\n                    \n                   (2016)."},{"key":"BFnrurol201716_CR122","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/77835","volume":"1","author":"RJ Binder","year":"2000","unstructured":"Binder, R. J., Han, D. K. & Srivastava, P. K. CD91: a receptor for heat shock protein gp96. Nat. Immunol. 1, 151\u2013155 (2000).","journal-title":"Nat. Immunol."},{"key":"BFnrurol201716_CR123","unstructured":"Steinberg, G.  et al. Phase I\/II study of patients with non-muscle invasive bladder cancer (NMIBC) treated with vesigenurtacel-L (HS-410) with or without bacillus Calmette\u2013Gu\u00e9rin (BCG). Presented at the AACR 2016 Annu Meet [online] \n                    http:\/\/content.stockpr.com\/heatbio\/db\/114\/1119\/file\/AACR+2016_HS-410_NMIBC_Phase1.pdf\n                    \n                   (2016)."},{"key":"BFnrurol201716_CR124","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02010203?term=02010203&rank=1\n                    \n                   (2016)."},{"key":"BFnrurol201716_CR125","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1158\/1078-0432.CCR-08-0126","volume":"14","author":"JL Gulley","year":"2008","unstructured":"Gulley, J. L.  et al. A pilot study to evaluate the safety and clinical outcomes of vaccination with recombinant CEA-MUC-1-TRICOM (PANVAC) poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 14, 3060\u20133069 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol201716_CR126","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02015104?term=02015104&rank=1\n                    \n                   (2017)."},{"key":"BFnrurol201716_CR127","doi-asserted-by":"publisher","first-page":"812","DOI":"10.4161\/cbt.25326","volume":"14","author":"EK Lee","year":"2013","unstructured":"Lee, E. K.  et al. A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin. Cancer Biol. Ther. 14, 812\u2013822 (2013).","journal-title":"Cancer Biol. Ther."},{"key":"BFnrurol201716_CR128","doi-asserted-by":"publisher","first-page":"885","DOI":"10.4161\/cbt.10.9.13237","volume":"10","author":"AR Metwalli","year":"2010","unstructured":"Metwalli, A. R.  et al. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol. Ther. 10, 885\u2013892 (2010).","journal-title":"Cancer Biol. Ther."},{"key":"BFnrurol201716_CR129","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1158\/1078-0432.CCR-12-1258","volume":"19","author":"X Yang","year":"2013","unstructured":"Yang, X.  et al. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clin. Cancer Res. 19, 148\u2013157 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol201716_CR130","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1166\/jbn.2014.1838","volume":"10","author":"S Cho","year":"2014","unstructured":"Cho, S.  et al. Functionalized gold nanorods for thermal ablation treatment of bladder cancer. J. Biomed. Nanotechnol. 10, 1267\u20131276 (2014).","journal-title":"J. Biomed. Nanotechnol."},{"key":"BFnrurol201716_CR131","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02009332?term=02009332&rank=1\n                    \n                   (2016)."},{"key":"BFnrurol201716_CR132","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0022-5347(01)63174-4","volume":"159","author":"CR Riedl","year":"1998","unstructured":"Riedl, C. R., Knoll, M., Plas, E. & Pfluger, H. Intravesical electromotive drug administration technique: preliminary results and side effects. J. Urol. 159, 1851\u20131856 (1998).","journal-title":"J. Urol."},{"key":"BFnrurol201716_CR133","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000052419","volume":"39","author":"R Colombo","year":"2001","unstructured":"Colombo, R.  et al. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication: a pilot study on marker lesion. Eur. Urol. 39, 95\u2013100 (2001).","journal-title":"Eur. Urol."},{"key":"BFnrurol201716_CR134","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1002\/cncr.28731","volume":"120","author":"BG Bachir","year":"2014","unstructured":"Bachir, B. G.  et al. Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette\u2013Guerin and electromotive mitomycin versus bacillus Calmette\u2013Guerin alone for patients with high-risk non-muscle-invasive bladder cancer. Cancer 120, 2424\u20132431 (2014).","journal-title":"Cancer"}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2017.16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2017.16","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2017.16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:18:26Z","timestamp":1684469906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2017.16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,21]]},"references-count":134,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["BFnrurol201716"],"URL":"https:\/\/doi.org\/10.1038\/nrurol.2017.16","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,21]]},"assertion":[{"value":"21 February 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.K. declares that he has acted as a consultant for Cepheid, Photocure,Telesta Therapeutics, Sanofi, Merck, Abbott Molecular, Theralase, Heat Biologics, Spectrum Pharmaceuticals, and Oncogenix. He has received grant support from FKD Industries, Photocure, Merck, and Heat Biologics, and he has a patent pending for a cytokine assay for BCG (CYPRIT) with the University of Texas MD Anderson Cancer Center. J.A.W. declares that he has acted as an adviser for MEL. J.P. declares clinical trial collaborations with Combat Medical and Presurgery. D.L. declares research collaborations with Vicinium and Cold Genesys-CG0070. R.B. declares that he has acted as a consultant for Sanofi. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}